^
Association details:
| Biomarker: | FLT3 D835A |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | PHI-101 (FLT3 inhibitor, Chk2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 4226: PHI-101, a next generation FLT3 inhibitor for acute myeloid leukemia
Published date:
06/23/2020
Excerpt:
It is active against a number of FLT3/ITD resistance mutations including FLT3/ITD/A627T, FLT3/ITD/N676D, FLT3/ITD/F691L, with IC50s of 0.1nM, 2.3nM, 14.6nM, respectively. It is also active against FLT3 kinase domain (FLT3/KD) resistance mutations, with IC50s against FLT3/D835A and FLT3/840GS of 5.3nM and 9.6nM, respectively.
DOI:
10.1158/1538-7445.AM2020-4226
